491 related articles for article (PubMed ID: 28264583)
1. CRISPR-Mediated Knockout of Cybb in NSG Mice Establishes a Model of Chronic Granulomatous Disease for Human Stem-Cell Gene Therapy Transplants.
Sweeney CL; Choi U; Liu C; Koontz S; Ha SK; Malech HL
Hum Gene Ther; 2017 Jul; 28(7):565-575. PubMed ID: 28264583
[TBL] [Abstract][Full Text] [Related]
2. Using CRISPR/Cas9 for Gene Knockout in Immunodeficient NSG Mice.
Du Y; Xie W; Zhang F; Choi U; Liu C; Sweeney CL
Methods Mol Biol; 2019; 1874():139-168. PubMed ID: 30353512
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease.
De Ravin SS; Li L; Wu X; Choi U; Allen C; Koontz S; Lee J; Theobald-Whiting N; Chu J; Garofalo M; Sweeney C; Kardava L; Moir S; Viley A; Natarajan P; Su L; Kuhns D; Zarember KA; Peshwa MV; Malech HL
Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077679
[TBL] [Abstract][Full Text] [Related]
4. Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair.
Sweeney CL; Pavel-Dinu M; Choi U; Brault J; Liu T; Koontz S; Li L; Theobald N; Lee J; Bello EA; Wu X; Meis RJ; Dahl GA; Porteus MH; Malech HL; De Ravin SS
Gene Ther; 2021 Jun; 28(6):373-390. PubMed ID: 33712802
[TBL] [Abstract][Full Text] [Related]
5. Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction.
Sweeney CL; Zou J; Choi U; Merling RK; Liu A; Bodansky A; Burkett S; Kim JW; De Ravin SS; Malech HL
Mol Ther; 2017 Feb; 25(2):321-330. PubMed ID: 28153086
[TBL] [Abstract][Full Text] [Related]
6. Chromosome Transplantation: Correction of the Chronic Granulomatous Disease Defect in Mouse Induced Pluripotent Stem Cells.
Castelli A; Susani L; Menale C; Muggeo S; Caldana E; Strina D; Cassani B; Recordati C; Scanziani E; Ficara F; Villa A; Vezzoni P; Paulis M
Stem Cells; 2019 Jul; 37(7):876-887. PubMed ID: 30895693
[TBL] [Abstract][Full Text] [Related]
7. Exon skipping in CYBB mRNA and skewed inactivation of X chromosome cause late-onset chronic granulomatous disease.
Eguchi M; Yagi C; Tauchi H; Kobayashi M; Ishii E; Eguchi-Ishimae M
Pediatr Hematol Oncol; 2018; 35(5-6):341-349. PubMed ID: 30633606
[TBL] [Abstract][Full Text] [Related]
8. CRISPR gene-engineered CYBB
Benyoucef A; Marchitto L; Touzot F
J Allergy Clin Immunol; 2020 Jun; 145(6):1690-1693.e5. PubMed ID: 31954113
[No Abstract] [Full Text] [Related]
9. Generation of novel Il2rg-knockout mice with clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9.
Byambaa S; Uosaki H; Hara H; Nagao Y; Abe T; Shibata H; Nureki O; Ohmori T; Hanazono Y
Exp Anim; 2020 Apr; 69(2):189-198. PubMed ID: 31801915
[TBL] [Abstract][Full Text] [Related]
10. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
[TBL] [Abstract][Full Text] [Related]
11. Chronic Granulomatous Disease and Myelodysplastic Syndrome in a Patient with a Novel Mutation in
Reis BCS; Cunha DP; Bueno APS; Carvalho FAA; Dutra J; Mello FV; Ribeiro MCM; Milito CB; da Costa ES; Vasconcelos Z
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680870
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression.
Wong RL; Sackey S; Brown D; Senadheera S; Masiuk K; Quintos JP; Colindres N; Riggan L; Morgan RA; Malech HL; Hollis RP; Kohn DB
Blood; 2023 Mar; 141(9):1007-1022. PubMed ID: 36332160
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-generated p47
Wrona D; Siler U; Reichenbach J
Sci Rep; 2017 Mar; 7():44187. PubMed ID: 28287132
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-gene-engineered CYBB knock-out PLB-985 cells, a useful model to study functional impact of X-linked chronic granulomatous disease mutations: application to the G412E X91+-CGD mutation.
Beaumel S; Verbrugge L; Fieschi F; Stasia MJ
Clin Exp Immunol; 2023 Apr; 212(2):156-165. PubMed ID: 36827093
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells.
Flynn R; Grundmann A; Renz P; Hänseler W; James WS; Cowley SA; Moore MD
Exp Hematol; 2015 Oct; 43(10):838-848.e3. PubMed ID: 26101162
[TBL] [Abstract][Full Text] [Related]
16. Chronic Granulomatous Disease: a Comprehensive Review.
Yu HH; Yang YH; Chiang BL
Clin Rev Allergy Immunol; 2021 Oct; 61(2):101-113. PubMed ID: 32524254
[TBL] [Abstract][Full Text] [Related]
17. Novel mutations in CYBB Gene Cause X-linked chronic Granulomatous Disease in Pakistani patients.
Gul I; Khan TA; Akbar NU; Gul N; Ali R; Khan SN
Ital J Pediatr; 2023 Aug; 49(1):95. PubMed ID: 37533075
[TBL] [Abstract][Full Text] [Related]
18. Genetic analysis of CYBB gene in 26 korean families with X-linked chronic granulomatous disease.
Ko SH; Rhim JW; Shin KS; Hahn YS; Lee SY; Kim JG
Immunol Invest; 2014; 43(6):585-94. PubMed ID: 24999735
[TBL] [Abstract][Full Text] [Related]
19. Hematologically important mutations: X-linked chronic granulomatous disease (fourth update).
Roos D; van Leeuwen K; Hsu AP; Priel DL; Begtrup A; Brandon R; Stasia MJ; Bakri FG; Köker N; Köker MY; Madkaika M; de Boer M; Garcia-Morato MB; Shephard JLV; Roesler J; Kanegane H; Kawai T; Di Matteo G; Shahrooei M; Bustamante J; Rawat A; Vignesh P; Mortaz E; Fayezi A; Cagdas D; Tezcan I; Kitcharoensakkul M; Dinauer MC; Meyts I; Wolach B; Condino-Neto A; Zerbe CS; Holland SM; Malech HL; Gallin JI; Kuhns DB
Blood Cells Mol Dis; 2021 Sep; 90():102587. PubMed ID: 34175765
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan.
Yanagimachi M; Kato K; Iguchi A; Sasaki K; Kiyotani C; Koh K; Koike T; Sano H; Shigemura T; Muramatsu H; Okada K; Inoue M; Tabuchi K; Nishimura T; Mizukami T; Nunoi H; Imai K; Kobayashi M; Morio T
Front Immunol; 2020; 11():1617. PubMed ID: 32849547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
